These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15766818)

  • 1. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.
    Duboc D; Meune C; Lerebours G; Devaux JY; Vaksmann G; Bécane HM
    J Am Coll Cardiol; 2005 Mar; 45(6):855-7. PubMed ID: 15766818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up.
    Duboc D; Meune C; Pierre B; Wahbi K; Eymard B; Toutain A; Berard C; Vaksmann G; Weber S; Bécane HM
    Am Heart J; 2007 Sep; 154(3):596-602. PubMed ID: 17719312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Did they lower stress in the trial? Or was it just wasted energy?
    Sanders SP
    J Am Coll Cardiol; 2005 Mar; 45(6):858-9. PubMed ID: 15766819
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
    Ramaciotti C; Heistein LC; Coursey M; Lemler MS; Eapen RS; Iannaccone ST; Scott WA
    Am J Cardiol; 2006 Sep; 98(6):825-7. PubMed ID: 16950195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
    Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
    BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
    Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
    Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
    Cleland JG; Tendera M; Adamus J; Freemantle N; Polonski L; Taylor J;
    Eur Heart J; 2006 Oct; 27(19):2338-45. PubMed ID: 16963472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive left ventricular dysfunction and myocardial fibrosis in Duchenne and Becker muscular dystrophy: a longitudinal cardiovascular magnetic resonance study.
    Aikawa T; Takeda A; Oyama-Manabe N; Naya M; Yamazawa H; Koyanagawa K; Ito YM; Anzai T
    Pediatr Cardiol; 2019 Feb; 40(2):384-392. PubMed ID: 30564867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
    Ogata H; Ishikawa Y; Ishikawa Y; Minami R
    J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life.
    Giglio V
    Am J Cardiol; 2007 Jan; 99(1):147-8. PubMed ID: 17196482
    [No Abstract]   [Full Text] [Related]  

  • 16. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.
    Buyse GM; Goemans N; van den Hauwe M; Thijs D; de Groot IJ; Schara U; Ceulemans B; Meier T; Mertens L
    Neuromuscul Disord; 2011 Jun; 21(6):396-405. PubMed ID: 21435876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
    Viollet L; Thrush PT; Flanigan KM; Mendell JR; Allen HD
    Am J Cardiol; 2012 Jul; 110(1):98-102. PubMed ID: 22463839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
    Tandon A; Villa CR; Hor KN; Jefferies JL; Gao Z; Towbin JA; Wong BL; Mazur W; Fleck RJ; Sticka JJ; Benson DW; Taylor MD
    J Am Heart Assoc; 2015 Mar; 4(4):. PubMed ID: 25814625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
    Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
    Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.